Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 3/20 | 0.67 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.67 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.67 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.67 |
| ▸ | SELP | P16109 | 1/20 | 0.64 |
| ▸ | DGKA | P23743 | 1/20 | 0.57 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.56 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.56 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.56 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1893444 | 1.00 | PRKCA (0.67) | PRKCAPRKCEPRKCQPRKCDSELP | |
| SCHEMBL565670 | 1.00 | PRKCA (0.67) | PRKCAPRKCEPRKCQPRKCDSELP | |
| SCHEMBL7076073 | 1.00 | PRKCA (0.67) | PRKCAPRKCEPRKCQPRKCDSELP | |
| SCHEMBL3403845 | 1.00 | PRKCA (0.67) | PRKCAPRKCEPRKCQPRKCDSELP | |
| SCHEMBL3408924 | 0.97 | SELP (0.69) | PRKCAPRKCEPRKCQPRKCDSELP | |
| SCHEMBL2228662 | 0.96 | SELP (0.68) | PRKCAPRKCEPRKCQPRKCDSELP | |
| SCHEMBL4195003 | 0.94 | PRKCA (0.60) | PRKCAPRKCEPRKCQPRKCDSELP | |
| SCHEMBL3408169 | 0.94 | SELP (0.65) | PRKCAPRKCEPRKCQPRKCDSELP | |
| SCHEMBL41701 | 0.94 | ALDH1A1 (0.63) | PRKCAPRKCEPRKCQPRKCDSELP | |
| SCHEMBL3409080 | 0.94 | ALDH1A1 (0.63) | PRKCAPRKCEPRKCQPRKCDSELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 320 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115316-A1 | LIPID NANOPARTICLES FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE, AND METHOD FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE USING SAME | NOF CORPORATION (JP) | 2026-04-30 | — | — | US | claimed |
| US-20260108473-A1 | BISPECIFIC STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING | GENERATION BIO CO (US) | 2026-04-23 | — | — | US | claimed |
| US-20260069620-A1 | IMMUNOTHERAPEUTIC PHOSPHOLIPIDS FOR CANCER TREATMENT | UNIVERSITY OF CINCINNATI (US) | 2026-03-12 | — | — | US | claimed |
| US-20260069535-A1 | NEBULIZER KITS AND USES THEREOF | PHARMOSA BIOPHARM INC (TW) | 2026-03-12 | — | — | US | claimed |
| EP-3820479-B1 | METHODS TO REDUCE COMPLICATIONS OF INTRA-ARTICULAR STEROID | TAIWAN LIPOSOME CO LTD (TW) | 2026-03-11 | — | — | EP | claimed |
| US-20260041643-A1 | STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING | GENERATION BIO CO (US) | 2026-02-12 | — | — | US | claimed |
| WO-2025245275-A1 | SURFACTANT PREPARATIONS FOR PULMONARY DELIVERY, AND METHODS FOR THE PREPARATION AND USE THEREOF | MOLECULAR EXPRESS, INC. (US) | 2025-11-27 | — | — | WO | claimed |
| WO-2025230917-A1 | METHODS FOR TREATING SYSTEMIC SCLEROSIS AND FROST BITE BY INHALATION THERAPY | PHARMOSA BIOPHARM INC. (TW) | 2025-11-06 | — | — | WO | claimed |
| WO-2025231217-A1 | COMPOSITIONS AND METHODS OF OLIGONUCLEOTIDE HITCHHIKING FOR ENCAPSULATION OF DRUGS IN LIPID NANOPARTICLES | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2025-11-06 | — | — | WO | claimed |
| US-12453706-B2 | Bispecific stealth lipid nanoparticle compositions for cell targeting | GENERATION BIO CO. (US) | 2025-10-28 | — | — | US | claimed |
| EP-0971699-A4 | METHOD FOR UTILIZING NEUTRAL LIPIDS TO MODIFY IN VIVO RELEASE FROM MULTIVESICULAR LIPOSOMES | SKYEPHARMA INC (US) | 2006-05-24 | — | — | EP | claimed |
| EP-1005326-A4 | METHOD FOR PRODUCING LIPOSOMES WITH INCREASED PERCENT OF COMPOUND ENCAPSULATED | SKYEPHARMA INC (US) | 2006-03-22 | — | — | EP | claimed |
| US-6241999-B1 | SUBSTITUTING FIRST AMPHIPATHIC LIPID WITH ONE HAVING A SIMILIAR STRUCTURE BUT MORE C ATOMS | SKYEPHARMA, INC. | 2001-06-05 | — | — | US | claimed |
| US-6193998-B1 | INCREASING EFFICIENCY USING MULTIVESICULAR LIPOSOMES CONTAINING PHOSPHOLIPIDS | SKYEPHARMA INC. | 2001-02-27 | — | — | US | claimed |
| US-6171613-B1 | REPLACING AMPHIPATHIC LIPIDS | SKYEPHARMA INC. | 2001-01-09 | — | — | US | claimed |
| EP-1005326-A1 | METHOD FOR PRODUCING LIPOSOMES WITH INCREASED PERCENT OF COMPOUND ENCAPSULATED | SkyePharma Inc. (US) | 2000-06-07 | — | — | EP | claimed |
| EP-0971699-A1 | METHOD FOR UTILIZING NEUTRAL LIPIDS TO MODIFY IN VIVO RELEASE FROM MULTIVESICULAR LIPOSOMES | SkyePharma Inc. (US) | 2000-01-19 | — | — | EP | claimed |
| US-5997899-A | INCREASING THE NUMBER OF CARBONS IN THE CARBON CHAIN OF AT LEAST ONE LIPID IN THE LIPID COMPONENT OF THE LIPOSOME, WHEREIN THE CHEMICAL STRUCTURES OF THE TWO LIPIDS ARE OTHERWISE SUBSTANTIALLY SIMILAR. | SKYEPHARMA INC. (US) | 1999-12-07 | — | — | US | claimed |
| WO-1998033483-A1 | METHOD FOR UTILIZING NEUTRAL LIPIDS TO MODIFY IN VIVO RELEASE FROM MULTIVESICULAR LIPOSOMES | SKYEPHARMA, INC. (US) | 1998-08-06 | — | — | WO | claimed |
| WO-1998014171-A1 | METHOD FOR PRODUCING LIPOSOMES WITH INCREASED PERCENT OF COMPOUND ENCAPSULATED | DEPOTECH CORPORATION (US) | 1998-04-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115316-A1 | LIPID NANOPARTICLES FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE, AND METHOD FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE USING SAME | SREBF1, SREBF2, FABP1 | PRKCA 1327/4885PRKCE 1888/4885PRKCQ 2988/4885 |
| US-20260069535-A1 | NEBULIZER KITS AND USES THEREOF | PTGER2, PTGER1, PTGIR | PRKCA 100/4885PRKCE 108/4885PRKCQ 103/4885 |
| US-12453706-B2 | Bispecific stealth lipid nanoparticle compositions for cell targeting | CD47, MCL1, PLTP | PRKCA 1603/4885PRKCE 1495/4885PRKCQ 1502/4885 |
| US-20260069620-A1 | IMMUNOTHERAPEUTIC PHOSPHOLIPIDS FOR CANCER TREATMENT | HSPA2, HSP90AB2P, HSPB1 | PRKCA 594/4885PRKCE 686/4885PRKCQ 966/4885 |
| US-20260041643-A1 | STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING | CD4, CD47, PBK | PRKCA 513/4885PRKCE 644/4885PRKCQ 808/4885 |
| US-20260108473-A1 | BISPECIFIC STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING | CD47, PLTP, CETP | PRKCA 1494/4885PRKCE 1724/4885PRKCQ 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.